文献速递心脑血管急症

血流储备分数指导的PCI五年结局

Five-Year Outcomes with PCI Guided by Fractional Flow Reserve.
PubMed 文献 · N Engl J Med · 2018-05-22
一句话结论稳定性冠心病患者中,FFR指导的PCI较单纯药物治疗显著降低5年死亡、心肌梗死或紧急血运重建复合终点(13.9% vs 27.0%,HR 0.46)。

FAME 2研究纳入1220例造影显示显著狭窄的稳定性冠心病患者,其中至少一处狭窄血流动力学显著(FFR≤0.80)者随机接受FFR指导的PCI联合药物治疗或单纯药物治疗,所有狭窄FFR均>0.80者进入注册队列接受药物治疗。888例随机分组(PCI组447例,药物组441例)。5年时PCI组主要复合终点(死亡、心肌梗死或紧急血运重建)发生率低于药物组(13.9% vs 27.0%;HR 0.46;95%CI 0.34-0.63;P<0.001),差异主要由紧急血运重建驱动(6.3% vs 21.1%;HR 0.27;95%CI 0.18-0.41)。两组死亡(5.1% vs 5.2%;HR 0.98;95%CI 0.55-1.75)和心肌梗死(8.1% vs 12.0%;HR 0.66;95%CI 0.43-1.00)无显著差异。PCI组与注册队列主要终点无显著差异(13.9% vs 15.7%;HR 0.88;95%CI 0.55-1.39)。PCI后心绞痛缓解较药物治疗更明显。

要点

  • 稳定性冠心病、至少一处狭窄FFR≤0.80者,FFR指导PCI联合药物治疗5年主要复合终点13.9% vs 单纯药物27.0%(HR 0.46;95%CI 0.34-0.63;P<0.001)。
  • 复合终点差异主要由紧急血运重建驱动:PCI组6.3% vs 药物组21.1%(HR 0.27;95%CI 0.18-0.41)。
  • 两组死亡无显著差异:PCI组5.1% vs 药物组5.2%(HR 0.98;95%CI 0.55-1.75)。
  • 两组心肌梗死无显著差异:PCI组8.1% vs 药物组12.0%(HR 0.66;95%CI 0.43-1.00)。
  • 所有狭窄FFR>0.80者仅药物治疗的注册队列5年主要终点15.7%,与PCI组13.9%无显著差异(HR 0.88;95%CI 0.55-1.39)。

适用人群与场景

  • 造影显示显著狭窄的稳定性冠心病患者,且至少一处狭窄血流动力学显著(FFR≤0.80)者随机分组。
  • 所有狭窄FFR均>0.80的患者进入注册队列接受药物治疗。

诊断标准与关键阈值

  • 血流动力学显著狭窄定义为FFR≤0.80。

研究设计与关键结果

  • 多中心随机对照试验,1220例患者中888例随机分组(PCI组447例,药物组441例)。
  • 主要终点为死亡、心肌梗死或紧急血运重建的复合终点;5年时PCI组13.9% vs 药物组27.0%(HR 0.46;95%CI 0.34-0.63;P<0.001)。
  • 紧急血运重建:PCI组6.3% vs 药物组21.1%(HR 0.27;95%CI 0.18-0.41)。
  • 死亡:PCI组5.1% vs 药物组5.2%(HR 0.98;95%CI 0.55-1.75),无显著差异。
  • 心肌梗死:PCI组8.1% vs 药物组12.0%(HR 0.66;95%CI 0.43-1.00),无显著差异。
  • PCI组与注册队列主要终点:13.9% vs 15.7%(HR 0.88;95%CI 0.55-1.39),无显著差异。
  • PCI后心绞痛缓解较药物治疗更明显。

证据类型、等级与局限

  • 随机对照试验(FAME 2,ClinicalTrials.gov NCT01132495),由St. Jude Medical等资助。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 对稳定性冠心病且至少一处狭窄FFR≤0.80的患者,初始FFR指导的PCI策略较单纯药物治疗降低5年死亡、心肌梗死或紧急血运重建复合终点,主要由紧急血运重建减少驱动。
  • 所有狭窄FFR>0.80的患者仅药物治疗长期结局良好。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: We hypothesized that fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) would be superior to medical therapy as initial treatment in patients with stable coronary artery disease.

METHODS: Among 1220 patients with angiographically significant stenoses, those in whom at least one stenosis was hemodynamically significant (FFR, ≤0.80) were randomly assigned to FFR-guided PCI plus medical therapy or to medical therapy alone. Patients in whom all stenoses had an FFR of more than 0.80 received medical therapy and were entered into a registry. The primary end point was a composite of death, myocardial infarction, or urgent revascularization.

RESULTS: A total of 888 patients underwent randomization (447 patients in the PCI group and 441 in the medical-therapy group). At 5 years, the rate of the primary end point was lower in the PCI group than in the medical-therapy group (13.9% vs. 27.0%; hazard ratio, 0.46; 95% confidence interval [CI], 0.34 to 0.63; P<0.001). The difference was driven by urgent revascularizations, which occurred in 6.3% of the patients in the PCI group as compared with 21.1% of those in the medical-therapy group (hazard ratio, 0.27; 95% CI, 0.18 to 0.41). There were no significant differences between the PCI group and the medical-therapy group in the rates of death (5.1% and 5.2%, respectively; hazard ratio, 0.98; 95% CI, 0.55 to 1.75) or myocardial infarction (8.1% and 12.0%; hazard ratio, 0.66; 95% CI, 0.43 to 1.00). There was no significant difference in the rate of the primary end point between the PCI group and the registry cohort (13.9% and 15.7%, respectively; hazard ratio, 0.88; 95% CI, 0.55 to 1.39). Relief from angina was more pronounced after PCI than after medical therapy.

CONCLUSIONS: In patients with stable coronary artery disease, an initial FFR-guided PCI strategy was associated with a significantly lower rate of the primary composite end point of death, myocardial infarction, or urgent revascularization at 5 years than medical therapy alone. Patients without hemodynamically significant stenoses had a favorable long-term outcome with medical therapy alone. (Funded by St. Jude Medical and others; FAME 2 ClinicalTrials.gov number, NCT01132495 .).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Xaplanteris P, Fournier S, Pijls NHJ, et al. Five-Year Outcomes with PCI Guided by Fractional Flow Reserve. N Engl J Med. 2018. PMID: 29785878. doi:10.1056/NEJMoa1803538

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。